N-Benzyl-N-[3-(4-chlorophenyl)-5-methylbenzofuran-2-ylmethyl]-N'-(2,4,6-trifluorophenyl)urea | 146011-65-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 英文名称: N-Benzyl-N-[3-(4-chlorophenyl)-5-methylbenzofuran-2-ylmethyl]-N'-(2,4,6-trifluorophenyl)urea
• 英文别名: 1-Benzyl-1-[[3-(4-chlorophenyl)-5-methyl-1-benzofuran-2-yl]methyl]-3-(2,4,6-trifluorophenyl)urea
• CAS: 146011-65-6
• 化学式: C₃₀H₂₂ClF₃N₂O₂
• 分子量: 534.965
• InChiKey: GJRPAGNTTAPJCC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.5
• 重原子数：
  38
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  45.5
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Urea derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0512570B1

  公开（公告）日：1995-10-11
• MEDICINAL COMPOSITION
  申请人：Astellas Pharma Inc.

  公开号：EP0943327B1

  公开（公告）日：2007-07-18
• JPH05140102A
  申请人：——

  公开号：JPH05140102A

  公开（公告）日：1993-06-08
• TREATING DISORDERS ASSOCIATED WITH ABERRANT ADRENOCORTICAL CELL BEHAVIOR
  申请人：Atterocor, Inc.

  公开号：US20150087649A1

  公开（公告）日：2015-03-26

  Methods and agents are provided for treatment of disorders associated with aberrant adrenocortical cell behavior, including (but not limited to) treatment of adrenocortical carcinoma (ACC) and/or Cushing's syndrome. Such methods involve administration of an agent which exhibits an IC 50 value against huACAT1 of less than 10 μM, and one or more further characteristics including effects on adrenocortical cells, disruption of cholesterol homeostasis, reduction in steroid biosynthesis, reduction of mitochondrial function, and/or preferential binding to by low-density lipoprotein (LDL).
• US6346537B1
  申请人：——

  公开号：US6346537B1

  公开（公告）日：2002-02-12

表征谱图